Tech Company Financing Transactions
TearSolutions Funding Round
TearSolutions secured a $8.1 million funding round on 12/20/2017. Backers included private investors.
Transaction Overview
Company Name
Announced On
12/20/2017
Transaction Type
Venture Equity
Amount
$8,056,619
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 24 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
315 Old Ivy Way 301
Charlottesville, VA 22903
USA
Charlottesville, VA 22903
USA
Phone
Website
Email Address
Not Recorded
Overview
Human tears supply and protect the surface of the eye. Several tear proteins are deficient in dry eye, the most common eye disease. One is essential and when reintroduced to dry eye tears, health is restored. Lacripep is a first-in-class topical synthetic peptide treatment for dry eye that addresses cause.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Mark Logan
Chief Executive Officer
Thomas Gadek
Chief Financial Officer
Colin Rolph
Chief Medical Officer
Marc Odrich
Chief Scientific Officer
Gordon Laurie
VP - Regulatory Affairs
Michelle Carpenter
Browse more venture capital transactions:
Prev: 12/20/2017: Label Insight venture capital transaction
Next: 12/20/2017: Ataata venture capital transaction
Share this article
News on VC Transactions
We report on funding rounds that are announced publicly. VC investment data records on this site are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs